Peer-reviewed veterinary case report
Masitinib slows growth of feline injection-site sarcoma cells in lab
By Lawrence, J et al.·Published in Veterinary and comparative oncology·2012·Department of Small Animal Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
- Species:
- cat
Plain-English summary
A study found that masitinib, a medication usually used for treating mast cell tumors in dogs, may also help cats with injection-site sarcomas (ISS). In tests with cancer cells from a primary ISS tumor and its lung metastasis, masitinib was effective at slowing down cell growth and affecting the signaling pathway involved in tumor growth. This suggests that masitinib could be a promising treatment option for cats suffering from this type of cancer. However, further research is needed to confirm its effectiveness in actual clinical settings.
People also search for: cat injection-site sarcoma treatment · masitinib for cats · feline cancer medication · cat tumor growth treatment
Abstract
Dysregulation of platelet-derived growth factor receptor (PDGFR) may play a role in feline injection-site sarcoma (ISS) cell growth and viability. Masitinib, a tyrosine kinase inhibitor approved for treatment of canine mast cell tumours, is highly selective for the PDGFR signalling pathway and may offer a new therapeutic approach for this disease. The in vitro effects of masitinib on growth, apoptosis and PDGFR signalling in two novel ISS cell lines were investigated. PDGFR expression was confirmed by Western blot in cell lines derived from a primary ISS tumour (JB) and a corresponding, histologically confirmed ISS lung metastasis (JBLM). Masitinib inhibited cell growth and PDGFR phosphorylation in both cell lines. Higher drug concentrations were required to inhibit growth than to modulate ligand-induced autophosphorylation of PDGFR. These in vitro data suggest that masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22236016/